Acute Efficacy of a Traditional Chinese Medicine for Treatment of Frequent Premature Ventricular Contractions in Patients with Concomitant Sinus Bradycardia: Results from a Double-Blind, Placebo-Controlled, Multicentre, Randomized Clinical Trial

Table 1

Baseline parameters between SSYXC and placebo group.

	Placebo group; n = 167	SSYXC group; n = 166	p value
Demographic characteristics
Age, years	57.2 (11.3)	56.2 (12.2)	0.45
Male (n)	89 (53%)	76 (46%)	0.17
History of symptoms, years	1.1 (0.5 - 3.3)	1.2 (0.4 - 2.8)	0.59
Height, cm	166.3 (7.6)	165.4 (7.1)	0.30
Weight, kg	65.2 (10.7)	64.4 (10.3)	0.51
Cardiac parameters
SBP, mmHg	126.9 (14.0)	126.8 (13.8)	0.98
DBP, mmHg	78.9 (8.6)	77.4 (8.6)	0.12
LVEF, %	61.7 (6.1)	61.4 (6.0)	0.72
LVDD, mm	48.5 (4.8)	48.6 (4.1)	0.81
Total heart beats per 24 hours	79,510 (8,730)	78,864 (7,764)	0.48
Mean heart rate, bpm	55.8 (3.0)	55.7 (3.3)	0.83
Total PVC, beats per 24 hours	2,755 (1,593 -5861)	2,793 (1,846 -5,980)	0.90
Symptom score
Baseline mean symptom score	7.0 (3.6)	6.9 (3.5)	0.68
Medical history
Hypertension	41 (25%)	50 (30%)	0.25
Diabetes mellitus	11 (7%)	12 (7%)	0.82
Hyperlipidemia	3 (2%)	7 (4%)	0.23
Treatment
Aspirin	20 (12%)	22 (13%)	0.73
ACEI/ARB	8 (5%)	9 (5%)	0.79
Calcium antagonists	25 (15%)	26 (16%)	0.86
Diuretics	4 (2%)	5 (3%)	0.75

SSYX = Shengsong Yangxin, SBP = systolic blood pressure, DBP = diastolic blood pressure, LVDD = left ventricular end-diastolic diameter, LVEF = left ventricular ejection fraction, bpm = beats per min, PVC = premature ventricular contractions, COPD = chronic obstructive pulmonary disease, ACEI = angiotensin converting enzyme inhibitors, and ARB = angiotensin receptor blocker.